109 related articles for article (PubMed ID: 27236032)
1. Expression and clinical significance of miRNAs that may be associated with the FHIT gene in breast cancer.
Sevinc ED; Cecener G; Ak S; Tunca B; Egeli U; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2016 Sep; 590(2):278-84. PubMed ID: 27236032
[TBL] [Abstract][Full Text] [Related]
2. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
4. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
6. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
7. Fhit induces the reciprocal suppressions between Lin28/Let-7 and miR-17/92miR.
Chae HJ; Seo JB; Kim SH; Jeon YJ; Suh SS
Int J Med Sci; 2021; 18(3):706-714. PubMed ID: 33437205
[No Abstract] [Full Text] [Related]
8. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
9. Correlations of breast cancer FHIT gene with the incidence and prognosis of breast cancer.
Fu Y; Shan X; Song W; Xu K; Jiao C; Zhang Q
J BUON; 2019; 24(1):40-47. PubMed ID: 30941950
[TBL] [Abstract][Full Text] [Related]
10. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
Yan LX; Huang XF; Shao Q; Huang MY; Deng L; Wu QL; Zeng YX; Shao JY
RNA; 2008 Nov; 14(11):2348-60. PubMed ID: 18812439
[TBL] [Abstract][Full Text] [Related]
12. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
13. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.
Liu XP; Yin XH; Yan XH; Zeng XT; Wang XH
Med Sci Monit; 2018 May; 24():3113-3118. PubMed ID: 29752880
[TBL] [Abstract][Full Text] [Related]
15. The significance of fragile histidine triad protein as a molecular prognostic marker of bladder urothelial carcinoma.
Zhang CT; Lu R; Lin YL; Liu RL; Zhang ZH; Yang K; Dang RF; Zhang HT; Shen YG; Kong PZ; Ren HL; Li XL; Quan W; Xu Y
J Int Med Res; 2012; 40(2):507-16. PubMed ID: 22613411
[TBL] [Abstract][Full Text] [Related]
16. microRNA-143 protects cells from DNA damage-induced killing by downregulating FHIT expression.
Lin YX; Yu F; Gao N; Sheng JP; Qiu JZ; Hu BC
Cancer Biother Radiopharm; 2011 Jun; 26(3):365-72. PubMed ID: 21711110
[TBL] [Abstract][Full Text] [Related]
17. Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.
Ginestier C; Bardou VJ; Popovici C; Charafe-Jauffret E; Bertucci F; Geneix J; Adélaïde J; Chaffanet M; Hassoun J; Viens P; Jacquemier J; Birnbaum D
Int J Cancer; 2003 Dec; 107(5):854-62. PubMed ID: 14566838
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
19. Down-regulated microRNA-124 expression as predictive biomarker and its prognostic significance with clinicopathological features in breast cancer patients.
Arabkheradmand A; Safari A; Seifoleslami M; Yahaghi E; Gity M
Diagn Pathol; 2015 Sep; 10():178. PubMed ID: 26415857
[TBL] [Abstract][Full Text] [Related]
20. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
